TickerTalks
Browse all tickers →
TickerTalks›$SCLX
SCSCLX

Scilex Holding Company

$SCLX·$80M·Drug Manufacturers - General·Healthcare
$8.76-7.2%YTD-28.1%1Y+38.6%
Mentions · last 7 days
2026-07-07: 11 posts2026-07-08: 10 posts2026-07-09: 2 posts2026-07-10: 1 posts2026-07-11: 1 posts2026-07-12: 2 posts2026-07-13: 10 posts37+8%
Price updated 1h ago·X counts updated 1d ago
SCSCLX
$SCLXScilex Holding Company
$8.76-7.20%37 posts+8%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $SCLX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-07-13

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Scilex just signed a $100M binding term sheet at $15 — a nano-cap pharma with a fresh capital anchor.

Scilex Holding Company is a small-cap pain-management pharmaceutical whose lead product ZTlido (lidocaine patch) has been ramping. This week's binding term sheet with iHolding Group for a $100M equity investment at $15/share is the specific capital-anchor event that reshapes the setup.

What the setup shows:

  • Revenue is growing but from a subscale base: Q1 revenue was $8.6M, up 72% year over year, with 48% gross margins but negative 373% operating margins — those numbers reflect a pre-scale specialty pharma where the ZTlido ramp is the fundamental story.
  • The $100M investment at $15 is materially above the current price: with SCLX at $9.48 and iHolding committing at $15, the term sheet effectively values the equity at 58% higher — that's a real vote of confidence, and it materially reduces near-term dilution risk against the burn rate.
  • The SCLX Stock Acquisition JV amendment is another positioning signal: SCLX Stock Acquisition JV LLC's Amendment No. 6 to Schedule 13D reflecting a change in position or intent — that's another institutional participant repositioning around the capital event, which typically precedes strategic actions.

September 2 earnings will be operational status; the real catalyst is the iHolding $100M closing and any additional strategic-partner disclosure. Absent the term sheet closing, the tape stays speculative — but the $15 anchor is a real fundamental improvement to the setup, and it's what separates SCLX from other nano-cap-pharma-with-a-hope stories.

What to watch: September 2 earnings, the iHolding $100M term-sheet closing, and any additional strategic-partner disclosure. Failure of the term sheet to close is what would flip the coil into a broken-story pattern.

On the calendar: 2026-09-02 — Q2 earnings

Read the AI verdict + X sentiment for $SCLX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Specialty pharma commercializing non-opioid pain products with the ZTlido lidocaine patch as its lead.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $SCLX.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $SCLX

Direct beneficiary — Specialty pharma commercializing non-opioid pain products with the ZTlido lidocaine patch as its lead; primary revenue lines track directly to the oral GLP-1 and obesity pipeline expansion and competition.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+16.3%YTD
+46.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
230%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-8.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-11.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
190%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
55.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 20, 2026$-4.76$-0.21-2166.5%
Q1 2026Apr 10, 2026$-4.60$-0.29-1471.9%
Q3 2025Nov 14, 2025$-22.17$-0.47-4617.0%
Q2 2025Aug 13, 2025$-7.42$-0.41-1709.8%
Next earningsWed, Sep 2·consensus EPS $-0.18

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$8.6M+72.1%48.4%-373%$-6.28$-4.2M
Q4 FY25$4.8M-67.8%12.3%-782%$-3.00$-18.0M
Q3 FY25$10.6M-26.8%68.5%-1766%$-22.17$8.5M
Q2 FY25$9.9M-39.5%66.9%-207%$-7.42$7.0M

Forward consensus

5-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$66.0M$66.0M – $66.0M-$0.55-$0.55 – -$0.551
FY27$189.0M$189.0M – $189.0M$0.45$0.45 – $0.451
FY28$608.5M$608.5M – $608.5M$4.22$4.22 – $4.221
FY29$944.2M$944.2M – $944.2M$6.79$6.79 – $6.791
FY30$1.1B$1.1B – $1.1B$7.83$7.83 – $7.831

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.17%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+23.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-17.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 7.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.735-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyApr 17Ma Stephen HoiCFO650.0K sh$780KSellApr 17Henry JiCEO650.0K sh$780KBuyApr 16Henry JiCEO3.3M sh$3.9M
+ 1 other (1 other) in window

See when $SCLX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentJul 7SC 13D/A
AI summary

SCLX Stock Acquisition JV LLC (managed by Xiao Xu, Palo Alto CA) filed Amendment No. 6 to its Schedule 13D for Scilex Holding Company as of July 3, 2026, reflecting a change in position or intent by this activist/large-holder entity. This is a recurring activist holder update for Scilex — the sixth amendment signals ongoing strategic interest or positioning changes by this entity in the clinical-stage pain therapeutics company.

8-KMaterial agreementJul 68-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
AI summary

Scilex Holding Company signed a binding term sheet on July 3, 2026 with iHolding Group LLP (Kazakhstan-based private investment group) for a $100 million equity investment at $15.00 per share (approximately 6,666,667 new shares). The proposed investment remains subject to definitive agreements, board approval, stockholder approval, and regulatory approvals — no assurance of closing was provided. At $15.00 per share with current market prices, this could represent either a premium or discount depending on trading levels; it would be materially dilutive if consummated.

8-KMaterial agreementJun 298-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale
AI summary

Scilex Holding entered a binding term sheet to purchase Bitcoin from Datavault AI Inc. (sourced from a Biconomy digital wallet), subject to execution of a definitive purchase agreement. This speculative treasury diversification move by a small commercial pharma company reflects the retail-driven trend of non-crypto companies adopting Bitcoin as a treasury asset. Final purchase remains subject to definitive documentation.

SC 13D/AActivist amendmentJun 26SC 13D/A
AI summary

Scilex Holding Company (SCLX) filed Amendment No. 2 to its Schedule 13D on Semnur Pharmaceuticals, Inc. as of June 15, 2026, reporting aggregate beneficial ownership of 181,520,112 shares — 78.85% of Semnur's outstanding common stock. The stake is held through wholly-owned subsidiary Scilex, Inc. (174,770,112 shares) and Scilex Bio, Inc. (6,250,000 shares), plus 500,000 shares held directly; SCLX also holds 100% of Semnur's Series A Preferred Stock voting on an as-converted basis. SCLX's 78.85% majority ownership of Semnur reflects dominant post-business-combination control over Semnur's assets and pipeline.

8-KShareholder voteJun 248-K — Item 5.07: Shareholder vote
AI summary

Scilex Holding Company held its 2026 Annual Meeting on June 24, 2026 with ~63.5% of common shares and 100% of Series A preferred stock represented (preferred votes on as-converted basis for ~848K aggregate votes). Three proposals were on the ballot; the high preferred stock concentration is a structural note for common shareholders. Body unavailable — excerpt truncated before full vote results are disclosed.

S-3Shelf registrationJun 2S-3
AI summary

Scilex Holding Company (SCLX) filed an S-3 shelf registration statement to register securities for future potential offerings; scope and total amount not specified in excerpt. Shelf registration enabling future capital raises with dilution potential.

8-KMaterial agreementMay 58-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

Scilex Holding (SCLX) disclosed that its subsidiary ACEA Therapeutics entered a Stock Acquisition Agreement (the 'ACEA-PHOE SAA') with Phoenix Asia Holdings on May 5, 2026, to transfer ACEA's stake in ACEA Pharma. The deal restructures Scilex's pharmaceutical asset holdings. The filing also includes a press release under Item 7.01 announcing the transaction.

8-KMaterial agreementApr 288-K — Item 1.01: Material agreement
AI summary

Scilex Holding (SCLX) entered a binding term sheet with Datavault AI Inc. on April 26, 2026, under which Datavault will make a cash contribution to Scilex in exchange for a revenue participation arrangement. The financial terms (contribution amount, revenue share rate) are described in exhibits. This is an alternative financing structure for the specialty pharmaceutical company.

+ 20 other (5 8-Ks · 2 S-8s · 2 EFFECTs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPglobenewswire.com·8d agoScilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026globenewswire.com·8d agoScilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPglobenewswire.com·9d agoOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheetgurufocus.com·19d agoOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheetprnewswire.com·19d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$PFE$JNJ$ABBV$MRK$GILD$AZN
Voices on X · last 7 days

No standout posts about $SCLX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport